ArticlePloS one2025
Potential of methanol extracts of Nephelium lappaceum (Sapindaceae) and Hyphaene thebaica (Arecaceae) as adjuvants to enhance the efficacy of antibiotics against critical class priority bacteria.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antibacterial activity of bioactive anthraquinones isolated from Cassia tora L. against pathogenic intestinal microorganisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- In vitro and in vivo antibacterial activities and phytochemical screening of 80% methanol extract from Ehretia cymosa leaves.PloS one · 2026Article
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botanicals have shown promise in mitigating antibiotic resistance in bacteria. This study examined the efficacy of methanolic extracts from two food plants (Nephelium lappaceum and Hyphaene thebaica), alone and in combination with antibiotics, against critical class priority bacteria, including multi-drug resistant (MDR) strains and clinical isolates of Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter aerogenes, and Escherichia coli. The herbals underwent testing using a 96-well microplate serial dilution technique before being analyzed for their effects on bacterial cell membrane integrity and H+-ATPase-mediated proton pumping. Phytochemical analysis was carried out using established techniques. The bioactive extracts displayed very good to weak antibacterial activities (128 ≤ MIC ≤ 2048 μg/mL). The bark, leaf, and peel extracts of N. lappaceum were found to be effective against all studied MDR bacteria. N. lappaceum leaf extract exhibited the best activity (128 ≤ MIC ≤ 1024 μg/mL on all studied MDR bacteria). Interestingly, all MBC/MIC ratios calculated were ≤ 4, suggesting bactericidal activities. N. lappaceum leaf extract has shown significant inhibition of bacterial H+-ATPase-mediated proton pumping and changes in the cell membrane integrity, suggesting possible modes of action. N. lappaceum (leaves and peels) and H. thebaica (fruits) extracts demonstrated a notable potential to synergize with tetracycline, vancomycin, imipenem, ciprofloxacin, and cefixime (up to 8-fold reduction of the antibiotic's MIC was recorded). N. lappaceum leaves and peels, and fruits of H. thebaica significantly improved the efficacy of all antibiotics tested against K. pneumoniae ATCC11296 at MIC/2. Similar effects were observed against P. aeruginosa PA01 and E. coli AG100, respectively, with leaves and peels of N. lappaceum. No antagonistic interactions were recorded. Qualitative phytochemical screening revealed the presence of tannins, phenols, and saponins in all test extracts. The findings of this study are promising and suggest that N. lappaceum and H. thebaica can be used either for direct action on bacteria or to revitalize outdated antibiotics that are gradually losing their potency due to resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.